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Respiratory function testsAbstract Rationale: Assessing the function of the right side of the heart along with diagnosing of
pulmonary hypertension and studying the hemodynamic abnormalities, thus studying functional
limitations of pulmonary hypertension on COPD patients.
Methods: Data from 51 COPD male patients between December 2012 and April 2013 were
reviewed. PFTs (post bronchodilators FEV1 6 0.7), echo, BODE index were obtained, RHC was
done only for 17 patients after their echo revealed PASPP 45 mmHg.
Results: We found 11 patients (21.5%) had MPAPP 25 mmHg by RHC (35.27 ± 7.837) and 2
patients (4%) had severe PH (MPAPP 40 mmHg). The mean age 62 (±9.16) with smoking index
34 (±6.5). 63% of the patients had PASPP 35 mmHg by echocardiography while 24 patients
(47%) had PASPP 45 mmHg. COPD patients with PH were more hypoxemic (53.73 ± 6.214
vs. 62.51 ± 10.999, p-value 0.00013), showed increased BODE index (8.45 ± 1.572 vs.
6.31 ± 2.604, p-value 0.0015), showed statistically signiﬁcant difference in both BRV and LRV
(3.725 ± 0.8625 vs. 4.500 ± 0.9849 p-value 0.0304 and 6.067 ± 0.9923 vs. 6.927 ± 0.7888, 0.006
respectively), showed a signiﬁcant difference in the measurement of TAPSE (2.055 ± 0.5298,
3.142 ± 0.3437 with p-value <0.0001) as compared to COPD patients without PH linear correla-
tion between PaO2 and BODE index with MPAP was noticed. 41 patients (80%) had LT E/A ratioed at a
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336 M. Soliman et al.less than 0.8 with statistically signiﬁcant difference between COPD patients with PH and those
without (0.518 ± 0.1991, 0.702 ± 0.4052 and p-value 0.0333). We found that echo (1) sensitivity
was about 65%, speciﬁcity of 50% with positive predictive value around 64% and negative predic-
tive value around 50% (2) 74% of the patients had >10 mmHg difference between PASP calculated
by echo and measured by RHC.
Conclusion: We conclude that PH in COPD patients is a common co-morbidity along with right
sided changes. Echo could be used with caution during assessment of PASP as it was inaccurate.
COPDPH patients had worse prognosis than COPD patients without PH.
Clinical impact: Screening for PH in any COPD is highly recommended as it affects the progno-
sis.
Echo could be used with caution during assessment of PASP in these patients.
ª 2014 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier
B.V. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD), a common
preventable and treatable disease, is characterized by persistent
airﬂow limitation that is usually progressive and associated
with an enhanced chronic inﬂammatory response in the air-
ways and the lung to noxious particles or gases. Exacerbations
and co-morbidities contribute to the overall severity in individ-
ual patients [1].
Pulmonary hypertension (PH) is considered one of the com-
mon complications of COPD, and the***** two are patholog-
ically interdependent [2].
COPD-associated PH (COPDPH) is increasingly recog-
nized as a poor prognostic marker. It is not only associated
with an increased risk of exacerbations but also associated
with worsened exercise capacity, oxygenation and mortality
[3–7].
The true incidence, prevalence and ideal management strat-
egies for COPD-associated PH are unknown. The overall
reported prevalence of PH in COPD ranges from 20 to 63%
[7–9].
It is difﬁcult to deﬁne this prevalence exactly, as the diag-
nostic criteria used in the literature vary with differing RHC
pressures and echocardiographic thresholds.
Despite that there have been signiﬁcant advances in under-
standing the underlying mechanisms in recent years, the path-
ophysiological mechanism responsible for the development of
COPDPH is incompletely understood. Endothelial dysfunc-
tion, vascular remodeling, inﬂammatory changes, alterations
in pulmonary mechanics and host genetic factors are the sug-
gested etiologies [2].
Right heart catheterization (RHC) is essential for a deﬁni-
tive diagnosis [2].
The principles of therapy continue to be: optimization of
overall COPD management with smoking cessation, bron-
chodilators and oxygen therapy; pulmonary rehabilitation;
and lung volume reduction surgery (LVRs) or lung transplan-
tation for appropriate candidates [10,11].
However, the advances in the therapy for pulmonary arte-
rial hypertension (PAH) have aroused interest in pharmacolog-
ical treatments for PH beyond World Health Organization
(WHO) group I.Subjects and methods
Subjects
The present study was conducted at the Chest Department of
the Kasr-El Aini hospital Cairo University in collaboration
with the Cardiology Department in the period between
December 2012 and April 2013.
The present study was conducted on COPD patients to
make an assessment of the function of the right side of the
heart along with diagnosing of pulmonary hypertension and
studying the hemodynamic abnormalities, to rule out possible
co morbidities in patients with severe pulmonary hypertension
(mean PAP > 40 mmHg) and studying functional limitations
of pulmonary hypertension on COPD patients.
Eighty-two patients had been enrolled in the study but ﬁfty-
one patients were eligible to the study according to the inclu-
sion criteria and 31 patients had been excluded; 12 patients
had left sided ventricular diastolic dysfunction grade II and
III, 17 patients were cardiac with EF less than 50% and 2
patients had portal HTN.
The Inclusion criteria were any stable COPD patient mild,
moderate or severe diagnosed according to GOLD 2013 crite-
ria by spirometry as post bronchodilator FEV1/FEV < 0.7,
while the patients with other types of PH had been excluded.
Methods
Prospective descriptive study through COPD patients who met
the inclusion criteria. Duration of the study lasting for
5 months for ﬁeld activities from December 2012 to April
2013 while data analysis and ﬁnal writing extended for
3 months from May to August 2013.
The eligible enrolled patients had undergone the following
workup: Complete history taking, full clinical examination,
WHO functional class assessment, pulmonary function tests
(using GOLD 2013 severity criteria), chest radiography,
6 min walk test (6 MWT), Arterial blood gases (ABG room
air), ECG and BODE index then calculated using MMRC
dyspnea scale.
ECHO heart done for all eligible patients using American
Society of Echocardiography guidelines 2010 where the
group(A) group(B) 
comorbidity 41.20% 81.80%
IHD 21.60% 45.50%
Arrythmia 3.90% 18%
cor pulomnale 23.00% 63.00%
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Figure 1 Co-morbidity prevelance.
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sided chamber dilatations by measuring BRV, MRV, LRV,
RA major dimension and RA minor dimension (2) Assessment
of RT. sided systolic function using TAPSE, LT.MPI and S
wave; (3) Assessment of RT. sided diastolic dysfunction by
measuring of Lt E wave, Lt A wave, and Lt E/A (4) Assess-
ment of PASP where SPAP can be estimated using TR veloc-
ity, and PADP can be estimated from the end-diastolic
pulmonary regurgitation velocity.
If PASP is more than 45 mmHg by echo heart; RHC after
written consent approved by the Cairo university ethics
research committee was done at RICU under complete aseptic
condition to invasively detect if PAP is either increased or
within normal levels and to study the hemodynamics of the
right side of the heart and pulmonary artery. RHC was per-
formed though internal jugular vein via anterior and posterior
approach with supplemental oxygen to maintain arterial oxy-
gen saturation at 90%. We measured the right atrial and ven-
tricular systolic, diastolic and mean pressure then PA systolic,
diastolic and mean pressures alongside PAWP. All hemody-
namic measurements are reported as the mean of three mea-
surements at end expiration. Mean pulmonary artery pressure
was calculated as the pulmonary artery diastolic pressure plus
one-third of the pulse pressure. Tricuspid or pulmonary valve
mechanical prosthesis or Right heart mass (thrombus and/or
tumor) and tricuspid or pulmonary valve endocarditis had been
excluded before the procedure by ECHO cardiography. Moni-
toring of the patients during and 8 h after the procedure for any
complications like arrhythmias, pneumothorax or hemothorax
was carried out.
Statistical analysis
The analysis of the collected data will be done according to the
design of the study (observational descriptive study) by using
the ANOVAs method. Data collected are tabulated and statis-
tically analyzed to reach their statistical signiﬁcance and their
important correlation.
Results
Fifty-one patients included in the study were exclusively males,
mean age about 59 ± 9.16 years old, while the mean age for
the patients having MPAPP 25 mmHg was 62 ± 7.42 with
EF more than 55% and their post bronchodilator FEV1 6 0.7.
Fifty-one patients had undergone the proposed diagnostic
workup to evaluate the right side of the heart where echocar-
diography was done for all patients and revealed 24 (47%)
patients had PASPP 45 while 27 (53%) had PASP < 45 after
explaining the RHC procedure for these patients, RHC after a
written consent was done for 16 patients and 8 patients refused
to do it and only one patient had PASP < 45 by ECHO heart
undergone RHC due to poor window for reliable estimation.
Two groups were identiﬁed; group (A) which includes all
the 51 patients eligible in the study and group (B) which
includes 11 patients whose MPAP was P25 mmHg measured
by RHC.
Smoking index was not signiﬁcantly different between the
two groups where 45 patients (88.2%) from Group (A) were
cigarette smokers with mean 1.8 (±4.07) pack/day and mean
cig. smoking index about 30 (±12.3) whereas all patients ingroup (B) were smokers with mean 2 pack/day and mean
smoking index about 34 (±6.5) {p-value 0.2779}.
Studying some of the co-morbid conditions revealed that 21
patients (41.2%) in group (A) had a co-morbid condition while
9 patients (81.8%) in group (B) had co-morbid condition and
distributed in Fig. 1.
Functional class assessment by mMRC was done for all eli-
gible patients and the results are shown in Fig. 2 for the two
groups where 55% of the patient in group (B) have functional
class IV where only 22% of the patients in group (A) have the
same functional class.
The ABG ﬁndings for the both groups are illustrated in
Table 1 where mean PaO2, PaCO2, PH, HCO3 and SO2 for
patients in group (A) were 62.51 (±10.999), 48.57
(±12.970), 7.3859 (±0.03590), 27.94 (±4.154), 88.7255%
(±5.51753%) respectively while in group (B) 53.73 (6.214),
63.64 (9.511), 7.3618 (0.03573), 32.64 (1.804), 84.1818%
(4.85424%) there was a signiﬁcant difference in PaO2, PaCO2,
HCO3 and SO2 between the two groups with p-value 0.00013,
0.0003, <0.0001, 0.0147, respectively.
ECHO heart assessment for RT. Sided chamber dimensions
with estimation of systolic, diastolic function and PASP was
for the patients in the both groups and results are illustrated
in Table 2.
BODE index for group (A) was 6.31 (±2.6) while 8.45
(±1.57) for group (B) and this difference was statistically sig-
niﬁcant between both groups {p-value 0.0015}.
Among the seventeen patients who had undergone RHC 11
patients (65%) had MPAP more than 25 mmHg while the
remaining 6 patients (35%) had MPAP less than 25 mmHg
echo sensitivity was about 65%, speciﬁcity of 50% with posi-
tive predictive value around 64% and negative predictive value
around 50%.
Among the eleven patients who had undergone RHC; only
two patients (12%) had MPAPP 40 mmHg and 9 patients
(53%) had MPAP between 25 and 39.
When using a different threshold for PAP detection the fol-
lowing will be obtained: (1) PASP > 35 mmHg by ECHO
heart PH was detected in 62.7% of the patients (2)
PASPP 45 mmHg was detected in 47% of the patients (3)
MPAPP 25 mmHg and PAWP 6 12 mmHg by RHC PH
was detected in only in 21.5% of the patients.
Right sided and PA hemodynamics were measured by RHC
and showed in Table 3 where the mean PA pressure for the
group(A) group(B) 
I 4% 0%
II 35% 9%
III 39% 36%
IV 22% 55%
0%
10%
20%
30%
40%
50%
60%
Figure 2 Functional class distribution.
Table 3 Right sided and PA hemodynamics.
N Minimum Maximum Mean Std. deviation
RAMP 11 4 26 9.82 6.524
Rt VMP 11 13 32 22.91 6.156
PAMP 11 25 50 35.27 7.837
PAWP 11 5 10 7.18 1.601
338 M. Soliman et al.patients undergoing RHC was 35.27 mmHg (±7.8) and mean
PAWP was 7.18 mmHg (±1.6).
The difference between the calculated PASP and measured
by RHC is shown in Fig. 3 where about 65% of the patients
were overestimated and had D PASPP 10 mmHg, 29.4%
D PASP within 10 mmHg while only about 6% were
underestimated.
Correlation between BODE index and MPAP was in a lin-
ear pattern as illustrated in Fig. 4 and this linear pattern is also
obtained from both correlations between MPAP and PaO2 as
it is illustrated by Fig. 5 and between MPAP and FEV1% as
illustrated in Fig. 6.
Discussion
The present study showed that the mean age for the all COPD
patients was about 59 (±SD 9.7) years while the mean age inTable 1 ABG ﬁndings with mean and standard deviations values.
ABG Group (A)
Mean Std. deviation
PaO2 62.51 10.999
PaCO2 48.57 12.970
pH 7.3859 0.03590
HCO3 27.94 4.154
SO2 88.7255% 5.51753%
Table 2 Echo ﬁndings.
Group (A) Group
N Mean Std. deviation N
BRV 51 3.725 0.8625 11
MRV 51 2.239 0.6582 11
LRV 51 6.067 0.9923 11
RA major 51 5.041 3.2125 11
RA minor 44 3.223 0.7054 11
TAPSE 51 3.142 0.3437 11
Lt MPI 45 0.4733 0.13316 11
Lt S wave 51 14.72 6.571 11
Lt E wave 51 11.23 6.074 11
Lt A wave 51 18.78 9.394 11
Lt E/A 51 0.702 0.4052 11
PASP 51 42.35 13.964 11the patient group who had MPAPP 25 mmHg by RHC was
62 (±SD 7.1, p-value 0.262) years which is not statistically sig-
niﬁcant, 51 patients were exclusively male and co-morbidity
was estimated to be 82% in the group that had
MPAPP 25 mmHg by RHC. So we could theorize two issues;
(1) PH might be a phenotype COPD showing more promi-
nence of co-morbidities or (2) patients showing co-morbidities
became more susceptible to PH. This is consistent with the
study done by Gartman et al. [9] and Fayngersh et al. [12] as
they showed that PH might be described in patients with
advanced age, however they asked either this association is
attributable to age alone, or other co morbidities contributing
to PH in the elderly.
The present study showed male sex predominance and this
might be directly related to COPD prevalence where it is more
common in males than females due to smoking habits, and this
is consistent with GOLD 2013 as it showed male predominance
of COPD.
The present study showed that the mean age for the
patients having MPAPP 25 mmHg was 62 (±9.16) with
smoking index 34 (±6.5) which suggests that cigarette smok-
ing may play an important role in the vascular changes occur-Group (B) p-Value
Mean Std. deviation
53.73 6.214 0.00013
63.64 9.511 0.0003
7.3618 0.03573 0.061
32.64 1.804 <0.0001
84.1818% 4.85424% 0.0147
(B) p-Value Abnormal values
Mean Std. deviation
4.500 0.9849 0.0304 >4.2
2.727 0.7072 0.0543 >3.5
6.927 0.7888 0.006 >8.6
4.445 0.7005 0.2351 >5.3
3.700 0.7912 0.0865 >4.4
2.055 0.5298 <0.0001 <1.6
0.4627 0.17182 0.8504 >0.55
17.09 4.011 0.1323 <10
11.27 4.628 0.9813 <35>73
22.73 8.063 0.1717 <21>40
0.518 0.1991 0.0333 <0.8
55.36 12.964 0.0092 >35
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Detection of right sided heart changes and pulmonary hypertension in COPD patients 339ring in the pulmonary circulation in COPD patients. Santos
et al. [13] and MacNee [14] showed structural changes might
be caused by the effects of cigarette smoke rather than hypox-
emia, these structural changes were found in patients with
mild, normoxaemic COPD and heavy smokers with normal
lung function. Chaouat et al. [15] showed that cigarette smoke
may induce pulmonary vascular remodeling at an early stage
of COPD.Cardiovascular disease is a frequent co-morbidity in
chronic obstructive pulmonary disease (COPD) as 45% of
the COPDPH patients in this study showed evidence of IHD
and 18% showed signs of arrhythmias. This agreed with Berry,
Wise [16] and Ekstrom [17] as they concluded that cardiovas-
cular disease is the cause of death and frequent co-morbidity
in COPD.
The present study showed that 36%, 55% COPDPH
patients proved by RHC were in WHO functional class III,
IV respectively. Judith et al. (2012) [18] (ASPIRE registry)
showed the percent functional class III/IV of mild to moderate
PH to severe PH was 74/12 and 61/36, respectively. So it was
suggested that when MPAP starts to increase in COPD espe-
cially if severe, pulmonary hemodynamics impairment impacts
functional class and exercise capacity. This is supported by
Leuchte et al. [19], Cuttica et al. [20].
Cor pulmonale was a frequent complication of COPDPH
as it was detected in about 63% but prediction of the mortality
or frequent exacerbation could not be concluded. While
Oswald et al. [21] with Kessler et al. [22,6] emphasize that
the presence of pulmonary hypertension (PH) and cor pulmo-
nale increases mortality and predicts hospital readmission for
exacerbations in patients with chronic obstructive pulmonary
disease (COPD).
The present study showed that: 62.7% has PASPP
35 mmHg, 47% had PASPP 45 mmHg by echo heart where
21.5% had MPAPP 25 mmHg and PAWP 6 12 mmHg by
RHC. Burrows et al. [7] had detected 20% of the study patients
had MPAPP 26 mmHg by RHC, Mykland et al. [8] showed
that 26% of his study patients had MPAPP 25 mmHg by
RHC while Gartman et al. [9] showed that 63% of the patients
had PASPP 35 mmHg by echocardiography. So the present
study conﬁrmed the diagnostic criteria used in the literature
vary with differing RHC pressures and echocardiographic
thresholds.
The present study showed that patients had
MPAPP 25 mmHg was more hypoxemic, had more severe
airway obstruction and both PaO2 and FEV1% showed a lin-
ear correlation with MPAP.
However, hypoxemia may be considered as a contributing
factor for development of PH as it supported by Marumo
et al. [23] or might be regarded as a result of the severity of
COPD as it was supported by GOLD 2013 So, it was thought
that PH in COPD patients is a multifactorial of diseases that
could be attributed to hypoxia, inﬂammation, remodeling to
endothelial dysfunction (as they reﬂect the severity of the dis-
ease) and this concept is consistent with Minai et al. [11].
The present study that mean PCO2 63.64 mmHg (±9.511)
with p-value 0.0003 while Judith et al. [18] (ASPIRE registry)
showed PCO2 around 40 mmHg. This hypoventilation might
be explained either by COPD alone or might be related to
affection of ventilatory reserve by PH or by both mechanisms,
this needs to be investigated.
An important issue may be considered as regards severe
form of PH (MPAPP 40 mmHg) that Boerrigter et al. [24]
showed that; not only the ventilatory reserve is affected but
also circulatory reserve might be affected in these type of
patients and this might explain further exercise intolerance
and worse functional class.
The present study showed that PAWP for all patients was
612 mmHg, in contrary Chabot et al. [25] showed a relatively
340 M. Soliman et al.high proportion of patients with COPD (19%) had an
increased pulmonary capillary wedge pressure at rest.
The present study found a difference between RVSP and
PASP which both were measured via RHC by 5 mmHg which
may be explained by large variations of pressure due to respi-
ratory swings which frequently observed in COPD and this
concept was supported by Minai et al. [11] who observed large
swings in the pressure in COPD patients.
In the present study; RHC was done for 16 patients having
PASPP 45 mmHg and one patient having PASP < 30 mmHg
but had a poor window that nine patients had MPAP between
25–39 (53%) and only two patients had MPAP more than
40 mmHg (12%), so most of the COPDPH patients range
from mild to moderate degree and this result is consistent with
result of Chaouat et al., Minai et al. [11] and Hostler et al. [2].
The assessment of right side dimensions; the present study
showed right ventricular enlargement in the basal dimensions
in 11 patients (21.5%) most of them had PH measured by
RHC, with statistically signiﬁcant difference in both BRV
and LRV between patients had PH and those do not have
(p-value 0.0304, 0.006 respectively). Xavier et al. [28] showed
right ventricular enlargement in 30% of patients, and this
was more pronounced in those with PH.
In the assessment of right ventricular systolic function; the
present study found statistically signiﬁcant difference between
COPD patients who had PH and those not have in the mea-
surement of TAPSE (2.055 ± 0.5298, 3.142 ± 0.3437 with p-
value <0.0001) although both of them had the normal value
of TAPSE, also LT.MPI and LT.S wave were within normal
values with no signiﬁcant changes between the two groups, this
is shown in Table 2.
In the assessment of right sided diastolic dysfunction
Table 2 showed that about 41 patients (80%) had LT E/A
ratio less than 0.8 and there was a statistically signiﬁcant dif-
ference between COPD patients had PH and those did not
have (0.518 ± 0.1991, 0.702 ± 0.4052 and p-value 0.0333).
In the echocardiographic assessment of PASP; there was
statistically signiﬁcant difference between the patients who
had PH conﬁrmed by RHC and those did not have
(55.36 ± 12.964, 42.35 ± 13.964 and p-value 0.0092). Fisher
et al. [29] were able to obtain DE estimates of RVSP in 66%
of 41 patients with COPD, and found a statistically signiﬁcant
correlation with invasive systolic pulmonary artery pressure.
The present study could not validate the equation created
by Chemla et al. [30] (MPAP = 0.6 · SPAP + 2) for non inva-
sive measurement of MPAP through PASP by DE as there was
a difference of more than 10 mmHg in 65% of the patients.
The present study in Table 3 showed the hemodynamics of
the right side of the heart and pulmonary artery through RHC
for 16 patients whose echo heart revealed PASPP 45 mmHg
and one patient whose PASP < 30 mmHg but had a poor
window for assessment where; RAMP was 9.82 mmHg
(±6.524), RT VMP was 22.91 mmHg (±6.156), PAMP was
35.27 mmHg (±7.837) and PAWP was 7.18 mmHg
(±1.601). 11 patients only had MPAPP 25 mmHg thus the
echo sensitivity was about 65%, speciﬁcity of 50% with posi-
tive predictive value around 64% and negative predictive value
around 50%. Fisher et al. [29] showed Transthoracic DE had a
sensitivity of 60% (95% conﬁdence intervals (CI) 42–76%), a
speciﬁcity of 74% (95% CI 58–87%), a positive predictive
value of 68% (95% CI 49–83%) and a negative predictive
value of 67% (95% CI 51–81%) as compared with RHC andthese results emphasize that the result of ECHO heart should
be interpreted cautiously in the COPD patients and the posi-
tive results need to be conﬁrmed by RHC.
The present study showed that echo heart is inaccurate in
the detection of PASP as compared with RHC where 64.7%
of the patients had >10 mmHg difference between PASP cal-
culated by echo and measured by RHC, while ARCASOY
et al. [31] found systolic PAP by echocardiography was possi-
ble in only 44% of the patients and 52% of pressure estima-
tions were found to be inaccurate. Fisher et al. [29] also
found that echocardiography was inaccurate by more than
10 mmHg in about one third of patients.
In this study right side changes and PH in COPD patients
are common complications and limiting exercise capacity and
this agreed with Burgess et al. [26], Barbera et al. [27], Berry,
Wise [16], and Ekstrom et al. [17].
The present study showed a linear relationship between
MPAP and BODE index as it captures elements that are
impacted by the presence of underlying PH, including both
the Medical Research Council (MRC) score and the 6-min
walk test distance.
The present study had faced a number of limiting factors
such as; (1) male gender predominance in the study that limits
the detection of prevalence in the female gender and (2) RHC
being an invasive costly procedure limit its using as a primary
tool of assessment of COPD-PH so we have to screen the
patients with DE.
The present study concluded that COPDPH patients have
more co-morbidity than COPD alone. The study supported
the concept of the diagnostic criteria used in the literature vary
with differing RHC pressures and echocardiographic thresh-
olds. The present study showed that patients having COPDPH
patients were more hypoxemic, had more severe airway
obstruction. The current study demonstrated that right side
changes and PH in COPD patients are common complications,
affecting survival, limiting exercise capacity. The study also
detected that ECHO heart sensitivity was about 65%, speciﬁc-
ity of 50% with 64.7% of the patients having>10 mmHg dif-
ference between PASP calculated by echo and measured by
RHC so it may be used as noninvasive screening method but
the results to be interpreted cautiously in COPD patients.
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